Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FL-101 |
Synonyms | |
Therapy Description |
FL-101 is a monoclonal antibody that targets interleukin-1 beta (IL-1b) and blocks its binding to the IL-1 receptor, potentially resulting in decreased IL-1b downstream signaling and inflammatory response, and inhibition of tumorigenesis and angiogenesis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FL-101 | FL 101|FL101|Anti-IL-1 Beta Monoclonal Antibody FL-101 | FL-101 is a monoclonal antibody that targets interleukin-1 beta (IL-1b) and blocks its binding to the IL-1 receptor, potentially resulting in decreased IL-1b downstream signaling and inflammatory response, and inhibition of tumorigenesis and angiogenesis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04758949 | Phase II | Nivolumab FL-101 + Nivolumab FL-101 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | Withdrawn | 0 |